Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The subject was randomized into Study M10-855 and completed through Week 26 in that study.~* The subject is receiving one or more antipsychotic medications.~Exclusion Criteria:~* Additional history collected during participation in Study M10-855 provides evidence that, in the investigator's judgement, the subject does not have schizophrenia.~* The subject experienced an adverse event or abnormal finding during physical examination, vital signs, laboratory profile, and/or electrocardiogram (ECG) measurements in Study M10-855 that indicates the subject is likely to become medically unstable during the current study.~* The subject is currently taking or is expected to be prescribed any excluded medication without the approval of AbbVie medical monitor.~* The subject is currently enrolled in, or plans to participate in, another interventional study during the course of this trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 66 Years
- Healthy Volunteers: f

Study Arms:
- ABT-126 low dose (Type: EXPERIMENTAL): ABT-126 low dose
- ABT-126 middle dose (Type: EXPERIMENTAL): ABT-126 middle dose
- ABT-126 high dose (Type: EXPERIMENTAL): ABT-126 high dose

Based on this trial design, predict the completion outcome and termination type (if applicable).